Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?

Abstract

The objective of this study is to determine whether pentraxin-3 (PTX-3) is clinically a biomarker of inflammation, a player in anti-inflammation, or both with regard to coronary atherosclerosis, we compared levels of PTX-3 with levels of adiponectin in addition to high-sensitivity C-reactive protein (hs-CRP). We enrolled 693 patients (51 % male; mean age 64 ± 12 years) at Fukuoka University Hospital. They were clinically suspected to have coronary artery disease (CAD) or had at least one cardiac risk factor and had undergone coronary computed tomography angiography (CTA). We evaluated the levels of PTX-3, hs-CRP, and adiponectin, the presence of CAD or metabolic factors, subcutaneous fat area, visceral fat area (VFA) and lipid profiles. The presence of CAD was independently associated with aging (p = 0.010) and the prevalence of hypertension (p < 0.0001), but not the levels of PTX-3, hs-CRP and adiponectin by a multivariate analysis. Although the number of significantly stenosed coronary vessels (VD) was not associated with PTX-3 or adiponectin, hs-CRP tended to increase as the number of VD increased. In addition, PTX-3 decreased as the number of metabolic factors increased, whereas hs-CRP increased as the number of metabolic factors increased. Interestingly, PTX-3 did not correlate with hs-CRP, but was positively correlated with adiponectin. In a multiple regression analysis, adiponectin (p = 0.003) and VFA (p = 0.008) were significant predictors of PTX-3 levels. In conclusion, PTX-3 and adiponectin showed similar associations with metabolic factors, whereas PTX-3 and hs-CRP showed opposite trends. Adiponectin and VFA were significant predictors of PTX-3 levels. PTX-3 might have an atheroprotective role as well as serving as a simple biomarker, like adiponectin.

Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality

“…For example, a proatherogenic role has been suggested for PTX3 in metabolic diseases [54, 55]. In contrast, the work of Nakamura et al [56] in coronary artery disease patients showed that PTX3 correlates to body fat and lipid profile in a comparable way to adiponectin—an atheroprotective adipokine— and opposite to CRP. Furthermore, in vivo studies showed that PTX3 is cardioprotective in acute myocardial infarction [57], while deficiency in this pentraxin promotes both vascular inflammation and atherosclerosis in mice [15].…”

Effect of coenzyme Q10 supplementation on serum of high sensitivity c-reactive protein level in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

“…In the pathogenesis of CVDs, inflammation plays a key role. [ 30 31 ] The serum level of hs-CRP cytokine increases in inflammatory conditions[ 5 ] and is related to developing CVDs. [ 32 ] In addition, CoQ10 influences inflammatory factors such as cytokines, so it can be useful for treating CVDs.…”

Pentraxin-3 Levels Relate to the Wells Score and Prognosis in Patients with Acute Pulmonary Embolism

“…There have been extensive recent studies investigating the roles of PTX-3 in vascular disease and angiogenesis [30, 31]. PTX-3 is produced not only by vascular smooth muscle cells and endothelial cells with localized inflammation but also by macrophages and monocytes in invasive lesions [23].…”